Emricasan (IDN-6556, PF-03491390) is a potent irreversible pan-caspase inhibitor with the ability to rapidly reduce elevated levels of serum ALT, AST and caspase mediated cleavage of cytokeratin-18 in HCV infected patients. 1,2,3 To date, emricasan has been studied in more than 550 individuals and has exhibited a safety profile similar to placebo.
Emricasan is currently in three Phase 2 clinical trials, including two trials in patients with liver cirrhosis. Here we report the effect of emricasan in healthy volunteers on measures of serum caspase activity and apoptosis. These results are compared with the effect of emricasan in subjects with varying degrees of hepatic impairment, as well as the effect of emricasan in subjects with severe renal impairment.
For research use only. We do not sell to patients.